1,4,7-triazacyclononane-n,n',n''-triacetic acid profile

1,4,7-triazacyclononane-N,N',N''-triacetic acid: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	124326
CHEMBL ID	2005280
SCHEMBL ID	173508
MeSH ID	M0140668

Synonym
nota
56491-86-2
1h-1,7-triazonine-1,4,7-triacetic acid, octahydro-
NCI60_034500
nsc696860
1h-1,4,7-triazonine-1,4,7-triacetic acid, hexahydro-
2-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]acetic acid
nsc-696860
2,2',2''-(1,4,7-triazonane-1,4,7-triyl)triacetic acid
AKOS016035272
67ga-9n3
hexahydro-1h-1,4,7-triazonine-1,4,7-triacetic acid
1,4,7-triazacyclononane-n,n',n''-triacetic acid
S6923
SCHEMBL173508
CHEMBL2005280 ,
JHALWMSZGCVVEM-UHFFFAOYSA-N
n,n',n''-tris(carboxymethyl)-1,4,7-triazacyclononane
1,4,7-triazacyclononane-n,n',n-triacetic acid
1,4,7-tricarboxymethyl-1,4,7-triazacyclononane
DTXSID60205034
FT-0699859
Z3235067151
1,4,7-triazacyclononane-1,4,7-triacetic acid
T3910
mfcd00137938
BS-46783
E78085
bdbm50452815
HY-134418
A902686
CS-0142067
BP-27907
2,2',2''-(1,4,7-triazonane-1,4,7-triyl)triaceticacid

Excerpt	Reference	Relevance
" In the toxicity study, no adverse effects were observed after injection of a 10 mg/kg dose of NOTA-2Rs15d."	( Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer. Caveliers, V; D'huyvetter, M; Devoogdt, N; Heemskerk, J; Keyaerts, M; Lahoutte, T; Muyldermans, S; Vaneycken, I; Vincke, C; Xavier, C, 2013)	0.39

Excerpt	Reference	Relevance
" Their promising in vivo pharmacokinetic performance may contribute to the improvement of the diagnostic imaging of tumors overexpressing GRPr."	( N-terminal modifications improve the receptor affinity and pharmacokinetics of radiolabeled peptidic gastrin-releasing peptide receptor antagonists: examples of 68Ga- and 64Cu-labeled peptides for PET imaging. Buchegger, F; Burian, A; Gourni, E; Jamous, M; Maecke, HR; Mansi, R; Reubi, JC; Smerling, C; Waser, B, 2014)	0.4
" A drug with a short half-life in the blood is less available at a target organ."	( Novel "Add-On" Molecule Based on Evans Blue Confers Superior Pharmacokinetics and Transforms Drugs to Theranostic Agents. Chen, H; Chen, X; Jacobson, O; Kiesewetter, DO; Liu, Y; Ma, Y; Niu, G; Weiss, ID; Wu, H, 2017)	0.46

Excerpt	Reference	Relevance
" Their antibacterial activities were tested in combination with meropenem (MEM) against several MBL (NDM and IMP type)-producing clinical isolates."	( Dithiocarbamates: Efficient metallo-β-lactamase inhibitors with good antibacterial activity when combined with meropenem. Chu, WC; Qin, SS; Wang, MM; Yang, QQ; Yang, Y; Zhang, E, 2018)	0.48
"The study is to evaluate biodistribution, dosimetry, safety, and clinical usefulness of F-AlF-NOTA-octreotide (F-OC) PET/CT in combination with F-FDG PET/CT for detection of neuroendocrine neoplasms (NENs)."	( Clinical Application of 18F-AlF-NOTA-Octreotide PET/CT in Combination With 18F-FDG PET/CT for Imaging Neuroendocrine Neoplasms. Chen, D; Hu, S; Li, J; Li, Y; Li, Z; Liu, Z; Long, T; Tang, Y; Yang, N; Zhou, M, 2019)	0.51

Excerpt	Reference	Relevance
"5%ID/g, presumably because of lower bioavailability due to more rapid clearance."	( Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts. Altai, M; Braun, A; Garske, U; Karlström, AE; Malmberg, J; Orlova, A; Perols, A; Sandström, M; Tolmachev, V; Varasteh, Z, 2012)	0.38

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Beta-lactamase	Escherichia coli	IC50 (µMol)	0.1095	0.1095	0.1095	0.1095	AID1369030
Beta-lactamase	Escherichia coli	Ki	5.1100	5.1100	5.1100	5.1100	AID1369031
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (64)

Assay ID	Title	Year	Journal	Article
AID1369012	Inhibition of NDM1 in Proteus mirabilis clinical isolates assessed as potentiation of meropenem-induced antibacterial activity by measuring meropenem MIC at 32 ug/ml incubated for 16 to 18 hrs by broth microdilution method (Rvb = 20 ug/ml)	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	NOTA analogue: A first dithiocarbamate inhibitor of metallo-β-lactamases.
AID1589190	Inhibition of NDM1 in Citrobacter freundii clinical isolate 7 assessed as potentiation of meropenem-induced antibacterial activity by measuring meropenem MIC after 24 hrs by broth microdilution assay (Rvb = 80 ug/ml)	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	H
AID1589246	Effect on growth of Enterobacter cloacae isolate 16 after 24 hrs by broth microdilution method	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	H
AID1589232	Effect on growth of Escherichia coli isolate 2 after 24 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	H
AID1589211	Inhibition of IMP4 in Proteus mirabilis isolate 19 assessed as potentiation of meropenem-induced antibacterial activity by measuring meropenem MIC after 24 hrs by broth microdilution method (Rvb = 320 ug/ml)	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	H
AID1589202	Inhibition of IMP4 in Klebsiella pneumoniae isolate 10 assessed as potentiation of meropenem-induced antibacterial activity by measuring meropenem MIC after 24 hrs by broth microdilution method (Rvb = 64 ug/ml)	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	H
AID1589248	Effect on growth of Escherichia coli isolate 18 after 24 hrs by broth microdilution method	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	H
AID1589210	Inhibition of IMP4 in Escherichia coli isolate 18 assessed as potentiation of meropenem-induced antibacterial activity by measuring meropenem MIC after 24 hrs by broth microdilution method (Rvb = 16 ug/ml)	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	H
AID1589207	Inhibition of IMP4 in Enterobacter cloacae isolate 15 assessed as potentiation of meropenem-induced antibacterial activity by measuring meropenem MIC after 24 hrs by broth microdilution method (Rvb = 32 ug/ml)	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	H
AID1589206	Inhibition of IMP4 in Escherichia coli isolate 14 assessed as potentiation of meropenem-induced antibacterial activity by measuring meropenem MIC after 24 hrs by broth microdilution method (Rvb = 16 ug/ml)	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	H
AID1589238	Effect on growth of Escherichia coli isolate 8 after 24 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	H
AID1589205	Inhibition of IMP4 in Klebsiella pneumoniae isolate 13 assessed as potentiation of meropenem-induced antibacterial activity by measuring meropenem MIC after 24 hrs by broth microdilution method (Rvb = 320 ug/ml)	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	H
AID1589203	Inhibition of IMP4 in Escherichia coli isolate 11 assessed as potentiation of meropenem-induced antibacterial activity by measuring meropenem MIC after 24 hrs by broth microdilution method (Rvb = 32 ug/ml)	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	H
AID1589249	Effect on growth of Proteus mirabilis isolate 19 after 24 hrs by broth microdilution method	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	H
AID1369043	Inhibition of NDM1 in Escherichia coli assessed as potentiation of 0.125 ug/ml meropenem-induced antibacterial activity by measuring bacterial count at 32 ug/ml incubated for 24 hrs by time-dependent killing assay (Rvb = 33884 log10CFU/ml)	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	NOTA analogue: A first dithiocarbamate inhibitor of metallo-β-lactamases.
AID1589195	Inhibition of NDM4 in Escherichia coli isolate 3 assessed as potentiation of meropenem-induced antibacterial activity by measuring meropenem MIC after 24 hrs by broth microdilution assay (Rvb = 1280 ug/ml)	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	H
AID1589237	Effect on growth of Citrobacter freundii isolate 7 after 24 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	H
AID1589234	Effect on growth of Enterobacter cloacae isolate 4 after 24 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	H
AID1589215	Inhibition of NDM4 in Escherichia coli isolate 3 assessed as potentiation of meropenem-induced bactericidal activity at 4 times MIC incubated for 24 hrs followed by replating on agar plates for 16 to 18 hrs and measured up to 24 hrs by time kill assay	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	H
AID1369011	Inhibition of NDM1 in Citrobacter freundii clinical isolates assessed as potentiation of meropenem-induced antibacterial activity by measuring meropenem MIC at 32 ug/ml incubated for 16 to 18 hrs by broth microdilution method (Rvb = 20 ug/ml)	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	NOTA analogue: A first dithiocarbamate inhibitor of metallo-β-lactamases.
AID1369010	Inhibition of NDM1 in Escherichia coli clinical isolates assessed as potentiation of meropenem-induced antibacterial activity by measuring meropenem MIC at 32 ug/ml incubated for 16 to 18 hrs by broth microdilution method (Rvb = 320 ug/ml)	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	NOTA analogue: A first dithiocarbamate inhibitor of metallo-β-lactamases.
AID1589235	Effect on growth of Enterobacter cloacae isolate 5 after 24 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	H
AID1369009	Inhibition of NDM1 in Escherichia coli clinical isolates assessed as potentiation of meropenem-induced antibacterial activity by measuring meropenem MIC at 32 ug/ml incubated for 16 to 18 hrs by broth microdilution method (Rvb = 10 ug/ml)	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	NOTA analogue: A first dithiocarbamate inhibitor of metallo-β-lactamases.
AID1589227	Inhibition of Escherichia coli NDM4 assessed as potentiation of meropenem-induced antibacterial activity by measuring reduction in bacterial growth at 64 ug/mL after 24 hrs by broth microdilution method relative to control	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	H
AID1589231	Effect on growth of Escherichia coli isolate 1 after 24 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	H
AID1369040	Effect on cell growth of Escherichia coli expressing NDM1 incubated for 16 to 18 hrs by CLSI protocol based method	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	NOTA analogue: A first dithiocarbamate inhibitor of metallo-β-lactamases.
AID1589191	Inhibition of NDM1 in Enterobacter cloacae isolate 6 assessed as potentiation of meropenem-induced antibacterial activity by measuring meropenem MIC after 24 hrs by broth microdilution assay (Rvb = 320 ug/ml)	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	H
AID1369032	Effect on cell growth of Escherichia coli expressing NDM1 assessed as cell growth level	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	NOTA analogue: A first dithiocarbamate inhibitor of metallo-β-lactamases.
AID1589204	Inhibition of IMP4 in Klebsiella pneumoniae isolate 12 assessed as potentiation of meropenem-induced antibacterial activity by measuring meropenem MIC after 24 hrs by broth microdilution method (Rvb = 16 ug/ml)	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	H
AID1369031	Non-competitive inhibition of NDM1 in Escherichia coli BL21 (DE3) using MEPM substrate incubated for 15 mins by UV spectroscopy based L-B plot	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	NOTA analogue: A first dithiocarbamate inhibitor of metallo-β-lactamases.
AID1589189	Inhibition of NDM1 in Escherichia coli isolate 8 assessed as potentiation of meropenem-induced antibacterial activity by measuring meropenem MIC after 24 hrs by broth microdilution assay (Rvb = 320 ug/ml)	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	H
AID1369008	Inhibition of NDM1 in Escherichia coli clinical isolates assessed as potentiation of meropenem-induced antibacterial activity by measuring meropenem MIC at 32 ug/ml incubated for 16 to 18 hrs by broth microdilution method (Rvb = 80 ug/ml)	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	NOTA analogue: A first dithiocarbamate inhibitor of metallo-β-lactamases.
AID1589242	Effect on growth of Klebsiella pneumoniae isolate 12 after 24 hrs by broth microdilution method	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	H
AID1589208	Inhibition of IMP4 in Enterobacter cloacae isolate 16 assessed as potentiation of meropenem-induced antibacterial activity by measuring meropenem MIC after 24 hrs by broth microdilution method (Rvb = 64 ug/ml)	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	H
AID1369013	Inhibition of NDM1 in Proteus mirabilis clinical isolates assessed as potentiation of meropenem-induced antibacterial activity by measuring meropenem MIC at 32 ug/ml incubated for 16 to 18 hrs by broth microdilution method (Rvb = 160 ug/ml)	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	NOTA analogue: A first dithiocarbamate inhibitor of metallo-β-lactamases.
AID1589209	Inhibition of IMP4 in Klebsiella pneumoniae isolate 17 assessed as potentiation of meropenem-induced antibacterial activity by measuring meropenem MIC after 24 hrs by broth microdilution method (Rvb = 32 ug/ml)	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	H
AID1369030	Inhibition of NDM1 in Escherichia coli BL21 (DE3) using MEPM substrate incubated for 15 mins by UV spectroscopy	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	NOTA analogue: A first dithiocarbamate inhibitor of metallo-β-lactamases.
AID1589236	Effect on growth of Enterobacter cloacae isolate 6 after 24 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	H
AID1589192	Inhibition of NDM1 in Enterobacter cloacae isolate 5 assessed as potentiation of meropenem-induced antibacterial activity by measuring meropenem MIC after 24 hrs by broth microdilution assay (Rvb = 640 ug/ml)	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	H
AID1369014	Inhibition of NDM1 in Proteus mirabilis clinical isolates assessed as potentiation of meropenem-induced antibacterial activity by measuring meropenem MIC at 32 ug/ml incubated for 16 to 18 hrs by broth microdilution method (Rvb = 40 ug/ml)	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	NOTA analogue: A first dithiocarbamate inhibitor of metallo-β-lactamases.
AID1589228	Inhibition of Escherichia coli NDM4 assessed as potentiation of meropenem-induced antibacterial activity by measuring bacterial growth rate at 64 ug/mL after 24 hrs in presence of ZnCl2 by broth microdilution method relative to control	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	H
AID1369044	Inhibition of NDM1 in Escherichia coli assessed as potentiation of 0.125 ug/ml meropenem-induced antibacterial activity by measuring bacterial count at 32 ug/ml incubated for 3 hrs by time-dependent killing assay (Rvb = 33884 log10CFU/ml)	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	NOTA analogue: A first dithiocarbamate inhibitor of metallo-β-lactamases.
AID1369016	Inhibition of NDM1 in Klebsiella pneumoniae clinical isolates assessed as potentiation of meropenem-induced antibacterial activity by measuring meropenem MIC at 32 ug/ml incubated for 16 to 18 hrs by broth microdilution method (Rvb = 80 ug/ml)	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	NOTA analogue: A first dithiocarbamate inhibitor of metallo-β-lactamases.
AID1589245	Effect on growth of Enterobacter cloacae isolate 15 after 24 hrs by broth microdilution method	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	H
AID1589244	Effect on growth of Escherichia coli isolate 14 after 24 hrs by broth microdilution method	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	H
AID1589233	Effect on growth of Escherichia coli isolate 3 after 24 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	H
AID1422108	Inhibition of Escherichia coli IMP4 assessed as potentiation of meropenem-induced antibacterial activity by measuring zone of inhibition at 10 uL after 16 to 18 hrs by disc diffusion method (Rvb = 9.8 +/- 0.6 millimeter)	2018	Bioorganic & medicinal chemistry letters, 11-15, Volume: 28, Issue:21	Dithiocarbamates: Efficient metallo-β-lactamase inhibitors with good antibacterial activity when combined with meropenem.
AID1589201	Inhibition of NDM1 in Escherichia coli isolate 9 assessed as potentiation of meropenem-induced antibacterial activity by measuring meropenem MIC after 24 hrs by broth microdilution assay (Rvb = 320 ug/ml)	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	H
AID1369045	Inhibition of NDM1 in Escherichia coli assessed as potentiation of 0.25 ug/ml meropenem-induced antibacterial activity by measuring bacterial count at 64 ug/ml incubated for 4 to 24 hrs by time-dependent killing assay (Rvb = 33884 log10CFU/ml)	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	NOTA analogue: A first dithiocarbamate inhibitor of metallo-β-lactamases.
AID1589226	Effect on growth of NDM4-positive Escherichia coli assessed as bacterial growth at 64 ug/mL after 24 hrs by broth microdilution method relative to control	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	H
AID1847347	Antibacterial activity against Escherichia coli expressing NDM-1 assessed as decrease in meropenem MIC at 4 mg/L incubated for 18 to 20 hrs by broth microdilution method	2021	European journal of medicinal chemistry, Nov-05, Volume: 223	Recent research and development of NDM-1 inhibitors.
AID1589196	Inhibition of NDM1 in Escherichia coli isolate 1 assessed as potentiation of meropenem-induced antibacterial activity by measuring meropenem MIC after 24 hrs by broth microdilution assay (Rvb = 1280 ug/ml)	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	H
AID1589193	Inhibition of NDM1 in Enterobacter cloacae isolate 4 assessed as potentiation of meropenem-induced antibacterial activity by measuring meropenem MIC after 24 hrs by broth microdilution assay (Rvb = 640 ug/ml)	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	H
AID1589239	Effect on growth of Escherichia coli isolate 9 after 24 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	H
AID1422107	Inhibition of Escherichia coli NDM4 assessed as potentiation of meropenem-induced antibacterial activity by measuring zone of inhibition at 10 uL after 16 to 18 hrs by disc diffusion method (Rvb = 9.6 +/- 0.5 millimeter)	2018	Bioorganic & medicinal chemistry letters, 11-15, Volume: 28, Issue:21	Dithiocarbamates: Efficient metallo-β-lactamase inhibitors with good antibacterial activity when combined with meropenem.
AID1369033	Inhibition of NDM1 in Escherichia coli assessed as potentiation of meropenem-induced antibacterial activity by measuring bacterial growth (Rvb = 90%)	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	NOTA analogue: A first dithiocarbamate inhibitor of metallo-β-lactamases.
AID1589194	Inhibition of NDM-7 in Escherichia coli isolate 2 assessed as potentiation of meropenem-induced antibacterial activity by measuring meropenem MIC after 24 hrs by broth microdilution assay (Rvb = 640 ug/ml)	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	H
AID1589240	Effect on growth of Klebsiella pneumoniae isolate 10 after 24 hrs by broth microdilution method	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	H
AID1369015	Inhibition of NDM1 in Klebsiella pneumoniae clinical isolates assessed as potentiation of meropenem-induced antibacterial activity by measuring meropenem MIC at 32 ug/ml incubated for 16 to 18 hrs by broth microdilution method (Rvb = 40 ug/ml)	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	NOTA analogue: A first dithiocarbamate inhibitor of metallo-β-lactamases.
AID1589241	Effect on growth of Escherichia coli isolate 11 after 24 hrs by broth microdilution method	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	H
AID1422120	Inhibition of Escherichia coli IMP4 assessed as potentiation of meropenem-induced bactericidal activity by measuring reduction in bacterial colonies at 4 to 8 times MIC incubated for 3 hrs followed by replating on agar plates and further incubated for 16	2018	Bioorganic & medicinal chemistry letters, 11-15, Volume: 28, Issue:21	Dithiocarbamates: Efficient metallo-β-lactamase inhibitors with good antibacterial activity when combined with meropenem.
AID1589247	Effect on growth of Klebsiella pneumoniae isolate 17 after 24 hrs by broth microdilution method	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	H
AID1369034	Inhibition of NDM1 in Escherichia coli assessed as potentiation of meropenem-induced antibacterial activity by measuring bacterial growth in presence of ZnCl2 (Rvb = 90%)	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	NOTA analogue: A first dithiocarbamate inhibitor of metallo-β-lactamases.
AID1589243	Effect on growth of Klebsiella pneumoniae isolate 13 after 24 hrs by broth microdilution method	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	H
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	4 (2.22)	18.7374
1990's	3 (1.67)	18.2507
2000's	3 (1.67)	29.6817
2010's	142 (78.89)	24.3611
2020's	28 (15.56)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	3 (1.54%)	5.53%
Reviews	5 (2.56%)	6.00%
Case Studies	10 (5.13%)	4.05%
Observational	0 (0.00%)	0.25%
Other	177 (90.77%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
benzaldehyde [no description available]	2.08	1	0	benzaldehydes	EC 3.1.1.3 (triacylglycerol lipase) inhibitor; EC 3.5.5.1 (nitrilase) inhibitor; flavouring agent; fragrance; odorant receptor agonist; plant metabolite
citric acid, anhydrous Citric Acid: A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium chelating ability.. citric acid : A tricarboxylic acid that is propane-1,2,3-tricarboxylic acid bearing a hydroxy substituent at position 2. It is an important metabolite in the pathway of all aerobic organisms.	2.06	1	0	tricarboxylic acid	antimicrobial agent; chelator; food acidity regulator; fundamental metabolite
chlorine chloride : A halide anion formed when chlorine picks up an electron to form an an anion.	3.38	2	0	halide anion; monoatomic chlorine	cofactor; Escherichia coli metabolite; human metabolite
aminocaproic acid Aminocaproic Acid: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.. 6-aminohexanoic acid : An epsilon-amino acid comprising hexanoic acid carrying an amino substituent at position C-6. Used to control postoperative bleeding, and to treat overdose effects of the thrombolytic agents streptokinase and tissue plasminogen activator.	2.1	1	0	amino acid zwitterion; epsilon-amino acid; omega-amino fatty acid	antifibrinolytic drug; hematologic agent; metabolite
pyridine azine : An organonitrogen compound of general structure RCH=N-N=CHR or RR'C=N-N=CRR'.	2.55	2	0	azaarene; mancude organic heteromonocyclic parent; monocyclic heteroarene; pyridines	environmental contaminant; NMR chemical shift reference compound
sarcosine cocobetaine: N-alkyl-betaine; cause of shampoo dermatitis	3.19	1	0	N-alkylglycine zwitterion; N-alkylglycine; N-methyl-amino acid; N-methylglycines	Escherichia coli metabolite; glycine receptor agonist; glycine transporter 1 inhibitor; human metabolite; mouse metabolite
aluminum fluoride [no description available]	4.11	4	0	aluminium coordination entity
benzamide benzamide : An aromatic amide that consists of benzene bearing a single carboxamido substituent. The parent of the class of benzamides.	2.13	1	0	benzamides
pentetic acid Pentetic Acid: An iron chelating agent with properties like EDETIC ACID. DTPA has also been used as a chelator for other metals, such as plutonium.	3.09	5	0	pentacarboxylic acid	copper chelator
embelin embelin: from Embelia fruit (Myrsinaceae). embelin : A member of the class of dihydroxy-1,4-benzoquinones that is 2,5-dihydroxy-1,4-benzoquinone which is substituted by an undecyl group at position 3. Isolated from Lysimachia punctata and Embelia ribes, it exhibits antimicrobial, antineoplastic and inhibitory activity towards hepatitis C protease.	3.41	1	0	dihydroxy-1,4-benzoquinones	antimicrobial agent; antineoplastic agent; hepatitis C protease inhibitor; plant metabolite
methadone Methadone: A synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of MORPHINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3). methadone : A racemate comprising equimolar amounts of dextromethadone and levomethadone. It is a opioid analgesic which is used as a painkiller and as a substitute for heroin in the treatment of heroin addiction.. 6-(dimethylamino)-4,4-diphenylheptan-3-one : A ketone that is heptan-3-one substituted by a dimethylamino group at position 6 and two phenyl groups at position 4.	3.7	1	1	benzenes; diarylmethane; ketone; tertiary amino compound
temozolomide [no description available]	3.7	1	1	imidazotetrazine; monocarboxylic acid amide; triazene derivative	alkylating agent; antineoplastic agent; prodrug
n,n,n',n'-tetrakis(2-pyridylmethyl)ethylenediamine N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine: a zinc ion chelating agent; structure given in first source. N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine : An N-substituted diamine that is ethylenediamine in which the four amino hydrogens are replaced by 2-pyridylmethyl groups.	3.41	1	0	N-substituted diamine; pyridines; tertiary amino compound	apoptosis inducer; chelator; copper chelator
zinc chloride zinc chloride: RN given refers to parent cpd. zinc dichloride : A compound of zinc and chloride ions in the ratio 1:2. It exists in four crystalline forms, in each of which the Zn(2+) ions are trigonal planar coordinated to four chloride ions.	2.06	1	0	inorganic chloride; zinc molecular entity	astringent; disinfectant; EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor; Lewis acid
edetic acid Edetic Acid: A chelating agent that sequesters a variety of polyvalent cations such as CALCIUM. It is used in pharmaceutical manufacturing and as a food additive.	4.27	5	0	ethylenediamine derivative; polyamino carboxylic acid; tetracarboxylic acid	anticoagulant; antidote; chelator; copper chelator; geroprotector
lactose Lactose: A disaccharide of GLUCOSE and GALACTOSE in human and cow milk. It is used in pharmacy for tablets, in medicine as a nutrient, and in industry.. lactose : A glycosylglucose disaccharide, found most notably in milk, that consists of D-galactose and D-glucose fragments bonded through a beta-1->4 glycosidic linkage. The glucose fragment can be in either the alpha- or beta-pyranose form, whereas the galactose fragment can only have the beta-pyranose form.. beta-lactose : The beta-anomer of lactose.	2.11	1	0	lactose
methionine Methionine: A sulfur-containing essential L-amino acid that is important in many body functions.. methionine : A sulfur-containing amino acid that is butyric acid bearing an amino substituent at position 2 and a methylthio substituent at position 4.	2.1	1	0	aspartate family amino acid; L-alpha-amino acid; methionine zwitterion; methionine; proteinogenic amino acid	antidote to paracetamol poisoning; human metabolite; micronutrient; mouse metabolite; nutraceutical
phenylalanine Phenylalanine: An essential aromatic amino acid that is a precursor of MELANIN; DOPAMINE; noradrenalin (NOREPINEPHRINE), and THYROXINE.. L-phenylalanine : The L-enantiomer of phenylalanine.. phenylalanine : An aromatic amino acid that is alanine in which one of the methyl hydrogens is substituted by a phenyl group.	2.21	1	0	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; phenylalanine; proteinogenic amino acid	algal metabolite; EC 3.1.3.1 (alkaline phosphatase) inhibitor; Escherichia coli metabolite; human xenobiotic metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
ampicillin Ampicillin: Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.. ampicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-phenylacetamido group.	3.41	1	0	beta-lactam antibiotic; penicillin allergen; penicillin	antibacterial drug
pyrroles 1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.	2.11	1	0	pyrrole; secondary amine
diethylene glycol glycol ether : A hydroxyether which contains both an ether and alcohol functional groups. It is one of the most versatile classes of organic solvents which are commonly used in paints, cleaners, adhesives, pharmaceuticals and cosmetics.	2.49	2	0	hydroxyether
evans blue Evans Blue: An azo dye used in blood volume and cardiac output measurement by the dye dilution method. It is very soluble, strongly bound to plasma albumin, and disappears very slowly.. Evans blue : An organic sodium salt that is the tetrasodium salt of 6,6'-{(3,3'-dimethyl[1,1'-biphenyl]-4,4'-diyl)bis[diazene-2,1-diyl]}bis(4-amino-5-hydroxynaphthalene-1,3-disulfonate). It is sometimes used as a counterstain, especially in fluorescent methods to suppress background autofluorescence.	3.41	6	0	organic sodium salt	fluorochrome; histological dye; sodium channel blocker; teratogenic agent
4-fluorobenzoic acid [no description available]	2.1	1	0	fluorobenzoic acid	bacterial xenobiotic metabolite
hesperidin Hesperidin: A flavanone glycoside found in CITRUS fruit peels.. hesperidin : A disaccharide derivative that consists of hesperetin substituted by a 6-O-(alpha-L-rhamnopyranosyl)-beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage.	3.41	1	0	3'-hydroxyflavanones; 4'-methoxyflavanones; dihydroxyflavanone; disaccharide derivative; flavanone glycoside; monomethoxyflavanone; rutinoside	mutagen
maleimide [no description available]	2.25	1	0	dicarboximide; maleimides	EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
durapatite Durapatite: The mineral component of bones and teeth; it has been used therapeutically as a prosthetic aid and in the prevention and treatment of osteoporosis.. hydroxylapatite : A phosphate mineral with the formula Ca5(PO4)3(OH).	2.5	2	0
cupric sulfide copper(II) sulfide : A copper sulfide in which the metal is in the +2 oxidation state.	2.11	1	0
pentachloromethylthiobenzene [no description available]	3.59	2	0
lutetium Lutetium: An element of the rare earth family of metals. It has the atomic symbol Lu, atomic number 71, and atomic weight 175.	2.49	2	0	d-block element atom; lanthanoid atom
manganese Manganese: A trace element with atomic symbol Mn, atomic number 25, and atomic weight 54.94. It is concentrated in cell mitochondria, mostly in the pituitary gland, liver, pancreas, kidney, and bone, influences the synthesis of mucopolysaccharides, stimulates hepatic synthesis of cholesterol and fatty acids, and is a cofactor in many enzymes, including arginase and alkaline phosphatase in the liver. (From AMA Drug Evaluations Annual 1992, p2035). manganese(4+) : A manganese cation that is monoatomic and has a formal charge of +4.	2.4	2	0	elemental manganese; manganese group element atom	Escherichia coli metabolite; micronutrient
platinum Platinum: A heavy, soft, whitish metal, resembling tin, with atomic number 78, atomic weight 195.084, symbol Pt. It is used in manufacturing equipment for laboratory and industrial use. It occurs as a black powder (platinum black) and as a spongy substance (spongy platinum) and may have been known in Pliny's time as alutiae.	2.31	1	0	elemental platinum; nickel group element atom; platinum group metal atom
scandium Scandium: An element of the rare earth family of metals. It has the atomic symbol Sc, atomic number 21, and atomic weight 45.	2.41	1	0	d-block element atom; rare earth metal atom; scandium group element atom
gadolinium Gadolinium: An element of the rare earth family of metals. It has the atomic symbol Gd, atomic number 64, and atomic weight 157.25. Its oxide is used in the control rods of some nuclear reactors.	2.68	3	0	f-block element atom; lanthanoid atom
aluminum chloride Aluminum Chloride: A compound with the chemical formula AlCl3; the anhydrous salt is used as a catalyst in organic chemical synthesis, and hydrated salts are used topically as antiperspirants, and for the management of HYPERHYDROSIS.	2.97	1	0	aluminium coordination entity	Lewis acid
misonidazole Misonidazole: A nitroimidazole that sensitizes normally radio-resistant hypoxic cells to radiation. It may also be directly cytotoxic to hypoxic cells and has been proposed as an antineoplastic.	2.11	1	0
fluorides [no description available]	4.29	5	0	halide anion; monoatomic fluorine
phenyl acetate phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.	3.89	11	0	benzenes; phenyl acetates
glutamic acid Glutamic Acid: A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.. glutamic acid : An alpha-amino acid that is glutaric acid bearing a single amino substituent at position 2.	2.1	1	0	glutamic acid; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; ferroptosis inducer; micronutrient; mouse metabolite; neurotransmitter; nutraceutical
alovudine [no description available]	2.11	1	0	pyrimidine 2',3'-dideoxyribonucleoside
azides Azides: Organic or inorganic compounds that contain the -N3 group.. azide : Any nitrogen molecular entity containing the group -N3.	2.52	2	0	pseudohalide anion	mitochondrial respiratory-chain inhibitor
captopril Captopril: A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin.. captopril : A L-proline derivative in which L-proline is substituted on nitrogen with a (2S)-2-methyl-3-sulfanylpropanoyl group. It is used as an anti-hypertensive ACE inhibitor drug.	3.41	1	0	alkanethiol; L-proline derivative; N-acylpyrrolidine; pyrrolidinemonocarboxylic acid	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
cyclen cyclen: macrocyclic polyamine metal-complexing agent. 1,4,7,10-tetraazacyclododecane : An azacycloalkane that is cyclododecane in which the carbon atoms at positions 1, 4, 7 and 10 are replaced by nitrogen atoms.	1.96	1	0	azacycloalkane; crown amine; saturated organic heteromonocyclic parent
baicalin [no description available]	3.41	1	0	dihydroxyflavone; glucosiduronic acid; glycosyloxyflavone; monosaccharide derivative	antiatherosclerotic agent; antibacterial agent; anticoronaviral agent; antineoplastic agent; antioxidant; cardioprotective agent; EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; ferroptosis inhibitor; neuroprotective agent; non-steroidal anti-inflammatory drug; plant metabolite; prodrug
fluorodeoxyglucose f18 Fluorodeoxyglucose F18: The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162)	3.83	9	0	2-deoxy-2-((18)F)fluoro-D-glucose; 2-deoxy-2-fluoro-aldehydo-D-glucose
bromopyruvate 3-bromopyruvic acid : A 2-oxo monocarboxylic acid that is pyruvic acid in which one of the methyl hydrogens is replaced by bromine. Synthetic brominated derivative and structural analog of pyruvic acid. Highly reactive alkylating agent. Anti-cancer drug	3.41	1	0	2-oxo monocarboxylic acid; organobromine compound; oxo carboxylic acid	alkylating agent; antineoplastic agent
magnolol [no description available]	3.41	1	0	biphenyls
fluoromisonidazole [no description available]	2.11	1	0
yttrium radioisotopes Yttrium Radioisotopes: Unstable isotopes of yttrium that decay or disintegrate emitting radiation. Y atoms with atomic weights 82-88 and 90-96 are radioactive yttrium isotopes.	2.15	1	0
arginyl-glycyl-aspartic acid arginyl-glycyl-aspartic acid: amino acid sequence of basic unit of widespread cellular recognition system	5.14	16	0	oligopeptide
1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid: structure given in first source. DOTA : An azamacrocyle in which four nitrogen atoms at positions 1, 4, 7 and 10 of a twelve-membered ring are each substituted with a carboxymethyl group.	5.43	18	0	azamacrocycle	chelator; copper chelator
gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate: RN refers to Na salt	1.96	1	0
s-(bismaleimidoethyl ether)cysteine [no description available]	2.54	2	0
carbapenems [no description available]	2.11	1	0
diamsar chelate diamsar chelate: structure given in first source; chelating agent, coordinate with metal being chelated	3.19	1	0
biotin vitamin B7 : Any member of a group of vitamers that belong to the chemical structural class called biotins that exhibit biological activity against vitamin B7 deficiency. Vitamin B7 deficiency is very rare in individuals who take a normal balanced diet. Foods rich in biotin are egg yolk, liver, cereals, vegetables (spinach, mushrooms) and rice. Symptoms associated with vitamin B7 deficiency include thinning hair, scaly skin rashes around eyes, nose and mouth, and brittle nails. The vitamers include biotin and its ionized and salt forms.	2.25	1	0	biotins; vitamin B7	coenzyme; cofactor; Escherichia coli metabolite; fundamental metabolite; human metabolite; mouse metabolite; nutraceutical; prosthetic group; Saccharomyces cerevisiae metabolite
organophosphonates hydrogenphosphite : A divalent inorganic anion resulting from the removal of a proton from two of the hydroxy groups of phosphorous acid.	2.07	1	0	divalent inorganic anion; phosphite ion
1,4,7-triazacyclononane 1,4,7-triazacyclononane: structure given in first source	2.07	1	0	azacycloalkane; crown amine; saturated organic heteromonocyclic parent
fibrin Fibrin: A protein derived from FIBRINOGEN in the presence of THROMBIN, which forms part of the blood clot.	2.52	2	0	peptide
meropenem Meropenem: A thienamycin derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of bacterial infections, including infections in immunocompromised patients.. meropenem : A carbapenemcarboxylic acid in which the azetidine and pyrroline rings carry 1-hydroxymethyl and in which the azetidine and pyrroline rings carry 1-hydroxymethyl and 5-(dimethylcarbamoyl)pyrrolidin-3-ylthio substituents respectively.	2.21	1	0	alpha,beta-unsaturated monocarboxylic acid; carbapenemcarboxylic acid; organic sulfide; pyrrolidinecarboxamide	antibacterial agent; antibacterial drug; drug allergen
ammonium acetate ammonium acetate : An ammonium salt obtained by reaction of ammonia with acetic acid. A deliquescent white crystalline solid, it has a relatively low melting point (114degreeC) for a salt. Used as a food acidity regulator, although no longer approved for this purpose in the EU.	2.06	1	0	acetate salt; ammonium salt	buffer; food acidity regulator
ditiocarb sodium [no description available]	2.17	1	0	organic molecular entity
thiourea Thiourea: A photographic fixative used also in the manufacture of resins. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance may reasonably be anticipated to be a carcinogen (Merck Index, 9th ed). Many of its derivatives are ANTITHYROID AGENTS and/or FREE RADICAL SCAVENGERS.. thiourea : The simplest member of the thiourea class, consisting of urea with the oxygen atom substituted by sulfur.	2.1	1	0	one-carbon compound; thioureas; ureas	antioxidant; chromophore
1,4,7-triazacyclononane-n,n',n''-tris(methylenephosphonate monoethyl ester) 1,4,7-triazacyclononane-N,N',N''-tris(methylenephosphonate monoethyl ester): a (31)P NMR probe for measurement of divalent cations in biological systems; structure given in first source	2.4	2	0
2-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid 2-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid: structure given in first source	2.1	1	0
4-azidophenylalanine 4-azidophenylalanine: RN given refers to (L)-isomer. 4-azido-L-phenylalanine : A 4-azidophenylalanine that has L-configuration. It is used as a bioorthogonal click-chemistry reagent.. 4-azidophenylalanine : A phenylalanine derivative that is phenylalanine substituted by an azido group at position 4.	2.21	1	0
arginyl-glycyl-aspartyl-phenylalanine [no description available]	2.08	1	0
ovalbumin Ovalbumin: An albumin obtained from the white of eggs. It is a member of the serpin superfamily.	3.7	1	1
pterostilbene [no description available]	3.41	1	0	diether; methoxybenzenes; stilbenol	anti-inflammatory agent; antineoplastic agent; antioxidant; apoptosis inducer; hypoglycemic agent; neuroprotective agent; neurotransmitter; plant metabolite; radical scavenger
sirolimus Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.	2.08	1	0	antibiotic antifungal drug; cyclic acetal; cyclic ketone; ether; macrolide lactam; organic heterotricyclic compound; secondary alcohol	antibacterial drug; anticoronaviral agent; antineoplastic agent; bacterial metabolite; geroprotector; immunosuppressive agent; mTOR inhibitor
su 11248 [no description available]	2.11	1	0	monocarboxylic acid amide; pyrroles	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; immunomodulator; neuroprotective agent; vascular endothelial growth factor receptor antagonist
aluminum Aluminum: A metallic element that has the atomic number 13, atomic symbol Al, and atomic weight 26.98.	3.33	6	0	boron group element atom; elemental aluminium; metal atom
gallium Gallium: A rare, metallic element designated by the symbol, Ga, atomic number 31, and atomic weight 69.72.. gallium atom : A metallic element predicted as eka-aluminium by Mendeleev in 1870 and discovered by Paul-Emile Lecoq de Boisbaudran in 1875. Named in honour of France (Latin Gallia) and perhaps also from the Latin gallus cock, a translation of Lecoq.	3.45	7	0	boron group element atom
cysteine Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.	3.02	4	0	cysteinium	fundamental metabolite
silicon Silicon: A trace element that constitutes about 27.6% of the earth's crust in the form of SILICON DIOXIDE. It does not occur free in nature. Silicon has the atomic symbol Si, atomic number 14, and atomic weight [28.084; 28.086].	3.64	2	0	carbon group element atom; metalloid atom; nonmetal atom
carbocyanines Carbocyanines: Compounds that contain three methine groups. They are frequently used as cationic dyes used for differential staining of biological materials.	2.25	1	0	cyanine dye; organic iodide salt	fluorochrome
everolimus [no description available]	2.08	1	0	cyclic acetal; cyclic ketone; ether; macrolide lactam; primary alcohol; secondary alcohol	anticoronaviral agent; antineoplastic agent; geroprotector; immunosuppressive agent; mTOR inhibitor
oxadiazoles Oxadiazoles: Compounds containing five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom which exist in various regioisomeric forms.	2.25	1	0
t140 peptide T140 peptide: a strong anti-hiv agent; amino acid sequence in first source	2.13	1	0
gastrins Gastrins: A family of gastrointestinal peptide hormones that excite the secretion of GASTRIC JUICE. They may also occur in the central nervous system where they are presumed to be neurotransmitters.	2.1	1	0
oligonucleotides [no description available]	2.13	1	0
n,n'-bis(2-hydroxy-5-(ethylene-beta-carboxy)benzyl)ethylenediamine n,n'-diacetic acid N,N'-bis(2-hydroxy-5-(ethylene-beta-carboxy)benzyl)ethylenediamine N,N'-diacetic acid: structure given in first source; a hexadentate ligand that chelates gallium; suitable for immunoscintigraphy with PET	2.13	1	0
exenatide Exenatide: A synthetic form of exendin-4, a 39-amino acid peptide isolated from the venom of the Gila monster lizard (Heloderma suspectum). Exenatide increases CYCLIC AMP levels in pancreatic acinar cells and acts as a GLUCAGON-LIKE PEPTIDE-1 RECEPTOR (GLP-1) agonist and incretin mimetic, enhancing insulin secretion in response to increased glucose levels; it also suppresses inappropriate glucagon secretion and slows gastric emptying. It is used an anti-diabetic and anti-obesity agent.	5.03	8	1
phthalocyanine phthalocyanine : A tetrapyrrole fundamental parent that consists of four isoindole-type units, with the connecting carbon atoms in the macrocycle replaced by nitrogen.	2.08	1	0	phthalocyanines; tetrapyrrole fundamental parent
duramycin duramycin: from Streptomyces cinnamoneus; contains rare amino acids such as lanthionine & lysinoarginine. lancovutide : A 19-membered heterodetic cyclic peptide that is isolated from Streptoverticillium cinnamoneus. It exhibits antiproliferative properties and induces apoptosis in tumour cells and has been used for treatment of cystic fibrosis.	2.6	1	0	heterodetic cyclic peptide; macrocycle	antimicrobial agent; apoptosis inducer; bacterial metabolite
adrenomedullin Adrenomedullin: A 52-amino acid peptide with multi-functions. It was originally isolated from PHEOCHROMOCYTOMA and ADRENAL MEDULLA but is widely distributed throughout the body including lung and kidney tissues. Besides controlling fluid-electrolyte homeostasis, adrenomedullin is a potent vasodilator and can inhibit pituitary ACTH secretion.	2.17	1	0
daptomycin [no description available]	3.7	1	1
vitamin b 12 Vitamin B 12: A cobalt-containing coordination compound produced by intestinal micro-organisms and found also in soil and water. Higher plants do not concentrate vitamin B 12 from the soil and so are a poor source of the substance as compared with animal tissues. INTRINSIC FACTOR is important for the assimilation of vitamin B 12.	2.1	1	0
gallium ga 68 dotatate gallium Ga 68 dotatate: A radioactive diagnostic agent used for POSITRON EMISSION TOMOGRAPHY (PET) imaging of SOMATOSTATIN RECEPTOR positive neuroendocrine tumors and malignant abdominal paraganglioma.	2.21	1	0
thromboplastin Thromboplastin: Constituent composed of protein and phospholipid that is widely distributed in many tissues. It serves as a cofactor with factor VIIa to activate factor X in the extrinsic pathway of blood coagulation.	2.07	1	0
folic acid folcysteine: used to promote fertility in chickens. vitamin B9 : Any B-vitamin that exhibits biological activity against vitamin B9 deficiency. Vitamin B9 refers to the many forms of folic acid and its derivatives, including tetrahydrofolic acid (the active form), methyltetrahydrofolate (the primary form found in blood), methenyltetrahydrofolate, folinic acid amongst others. They are present in abundance in green leafy vegetables, citrus fruits, and animal products. Lack of vitamin B9 leads to anemia, a condition in which the body cannot produce sufficient number of red blood cells. Symptoms of vitamin B9 deficiency include fatigue, muscle weakness, and pale skin.	2.83	3	0	folic acids; N-acyl-amino acid	human metabolite; mouse metabolite; nutrient

Condition	Relationship Strength	Studies	Trials
Extravascular Hemolysis [description not available]	2.17	1	0
Hemolysis The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.	2.17	1	0
Signet Ring Cell Carcinoma [description not available]	2.31	1	0
Carcinoma, Signet Ring Cell A poorly differentiated adenocarcinoma in which the nucleus is pressed to one side by a cytoplasmic droplet of mucus. It usually arises in the gastrointestinal system.	2.31	1	0
Cancer of Stomach [description not available]	2.31	1	0
Stomach Neoplasms Tumors or cancer of the STOMACH.	2.31	1	0
Carcinoma, Small Cell Lung [description not available]	2.41	1	0
Cancer of Lung [description not available]	3.04	4	0
Lung Neoplasms Tumors or cancer of the LUNG.	3.04	4	0
Small Cell Lung Carcinoma A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).	2.41	1	0
Cancer of Kidney [description not available]	2.57	2	0
Kidney Neoplasms Tumors or cancers of the KIDNEY.	2.57	2	0
Angiomyolipoma A benign tumor containing vascular, adipose, and muscle elements. It occurs most often in the kidney with smooth muscle elements (angiolipoleiomyoma) in association with tuberous sclerosis. (Dorland, 27th ed)	2.41	1	0
Acute Confusional Senile Dementia [description not available]	2.41	1	0
Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)	2.41	1	0
Diffuse Large B-Cell Lymphoma [description not available]	3.65	5	0
Lymphoma, Large B-Cell, Diffuse Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.	3.65	5	0
Familial Nonmedullary Thyroid Cancer [description not available]	2.6	1	0
Cancer of the Thyroid [description not available]	2.59	2	0
Thyroid Neoplasms Tumors or cancer of the THYROID GLAND.	2.59	2	0
Cirrhosis [description not available]	2.72	2	0
Kahler Disease [description not available]	3.01	3	0
Fibrosis Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.	2.72	2	0
Kidney Diseases Pathological processes of the KIDNEY or its component tissues.	2.6	1	0
Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.	3.01	3	0
2019 Novel Coronavirus Disease [description not available]	6.01	5	4
Perforated Appendicitis [description not available]	2.6	1	0
Acute Disease Disease having a short and relatively severe course.	2.6	1	0
Appendicitis Acute inflammation of the APPENDIX. Acute appendicitis is classified as simple, gangrenous, or perforated.	2.6	1	0
Diffuse Mixed Small and Large Cell Lymphoma [description not available]	2.21	1	0
Lymphoma, Non-Hodgkin Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.	2.21	1	0
Benign Neoplasms [description not available]	4.71	10	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	4.71	10	0
Cancer of Prostate [description not available]	5.11	15	0
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	5.11	15	0
Lymphangiomyomatosis [description not available]	2.25	1	0
Lymphangioleiomyomatosis A disease characterized by the progressive invasion of SMOOTH MUSCLE CELLS into the LYMPHATIC VESSELS, and the BLOOD VESSELS. The majority of the cases occur in the LUNGS of women of child-bearing age, eventually blocking the flow of air, blood, and lymph. The common symptom is shortness of breath (DYSPNEA).	2.25	1	0
Astrocytoma, Grade IV [description not available]	5.04	8	1
Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.	5.04	8	1
Experimental Neoplasms [description not available]	2.95	4	0
Benign Neoplasms, Brain [description not available]	2.83	3	0
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	2.83	3	0
Diffuse Parenchymal Lung Disease [description not available]	3.7	1	1
Atherogenesis [description not available]	3.7	1	1
Atheroma [description not available]	3.97	2	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	6.6	12	4
Idiopathic Parkinson Disease [description not available]	3.7	1	1
Infections, Staphylococcal [description not available]	4.24	3	1
Bacterial Endocarditides [description not available]	3.7	1	1
Endocarditis, Bacterial Inflammation of the ENDOCARDIUM caused by BACTERIA that entered the bloodstream. The strains of bacteria vary with predisposing factors, such as CONGENITAL HEART DEFECTS; HEART VALVE DISEASES; HEART VALVE PROSTHESIS IMPLANTATION; or intravenous drug use.	3.7	1	1
Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)	3.7	1	1
Staphylococcal Infections Infections with bacteria of the genus STAPHYLOCOCCUS.	4.24	3	1
Lung Diseases, Interstitial A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features.	3.7	1	1
Neuroendocrine Tumors Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.	4.31	3	1
Atherosclerosis A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.	3.7	1	1
Lymphoma of Mucosa-Associated Lymphoid Tissue [description not available]	2.41	1	0
Lymphoma, B-Cell, Marginal Zone Extranodal lymphoma of lymphoid tissue associated with mucosa that is in contact with exogenous antigens. Many of the sites of these lymphomas, such as the stomach, salivary gland, and thyroid, are normally devoid of lymphoid tissue. They acquire mucosa-associated lymphoid tissue (MALT) type as a result of an immunologically mediated disorder.	2.41	1	0
Angiogenesis, Pathologic [description not available]	3.78	10	0
Carcinoma, Anaplastic [description not available]	2.54	2	0
Adenoma, beta-Cell [description not available]	4.77	6	1
Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.	2.54	2	0
Insulinoma A benign tumor of the PANCREATIC BETA CELLS. Insulinoma secretes excess INSULIN resulting in HYPOGLYCEMIA.	4.77	6	1
Colorectal Cancer [description not available]	2.73	3	0
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	2.73	3	0
Fibrosarcoma A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed)	2.17	1	0
Endothelioma, Lymphatic [description not available]	2.17	1	0
Lymphangioma A benign tumor resulting from a congenital malformation of the lymphatic system. Lymphangioendothelioma is a type of lymphangioma in which endothelial cells are the dominant component.	2.17	1	0
Cancer of Colon [description not available]	2.5	2	0
Cancer of Pancreas [description not available]	4.89	7	1
Colonic Neoplasms Tumors or cancer of the COLON.	2.5	2	0
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	4.89	7	1
Acinetobacter Infections Infections with bacteria of the genus ACINETOBACTER.	2.21	1	0
Breast Cancer [description not available]	3.35	6	0
Neoplasms, Nervous System [description not available]	2.21	1	0
Breast Neoplasms Tumors or cancer of the human BREAST.	3.35	6	0
Carcinogenesis The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.	2.21	1	0
Congenital Familial Lymphedema [description not available]	2.21	1	0
Lymphedema Edema due to obstruction of lymph vessels or disorders of the lymph nodes.	2.21	1	0
Cancer of the Uterus [description not available]	2.21	1	0
Uterine Neoplasms Tumors or cancer of the UTERUS.	2.21	1	0
Rheumatoid Arthritis [description not available]	2.21	1	0
Allergic Encephalomyelitis [description not available]	2.21	1	0
Experimental Lung Inflammation Inflammation of any part, segment or lobe, of the lung parenchyma.	2.21	1	0
Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.	2.21	1	0
Dermatitis Any inflammation of the skin.	2.21	1	0
Pneumonia Infection of the lung often accompanied by inflammation.	2.21	1	0
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	3.94	4	0
Injury, Myocardial Reperfusion [description not available]	2.52	2	0
Metastase [description not available]	3.05	4	0
Cancer of Rectum [description not available]	2.21	1	0
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	3.05	4	0
Rectal Neoplasms Tumors or cancer of the RECTUM.	2.21	1	0
Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.	4.03	13	0
Cardiovascular Stroke [description not available]	2.78	3	0
Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).	2.78	3	0
Infection [description not available]	2.1	1	0
Innate Inflammatory Response [description not available]	3.02	4	0
Infections Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.	2.1	1	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	3.02	4	0
B16 Melanoma [description not available]	2.52	2	0
Blood Clot [description not available]	2.1	1	0
Thrombosis Formation and development of a thrombus or blood clot in the blood vessel.	2.1	1	0
Adenocarcinoma, Basal Cell [description not available]	2.1	1	0
Lymph Node Metastasis [description not available]	2.1	1	0
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	2.1	1	0
Polyarthritis [description not available]	2.11	1	0
Arthritis Acute or chronic inflammation of JOINTS.	2.11	1	0
Cancer of Mouth [description not available]	2.1	1	0
Mouth Neoplasms Tumors or cancer of the MOUTH.	2.1	1	0
Neoplasm Metastasis, Unknown Primary [description not available]	2.11	1	0
Experimental Mammary Neoplasms [description not available]	2.49	2	0
Disease Exacerbation [description not available]	2.11	1	0
Abdominal Aortic Aneurysm [description not available]	2.11	1	0
Aortic Aneurysm, Abdominal An abnormal balloon- or sac-like dilatation in the wall of the ABDOMINAL AORTA which gives rise to the visceral, the parietal, and the terminal (iliac) branches below the aortic hiatus at the diaphragm.	2.11	1	0
Arterial Diseases, Carotid [description not available]	2.11	1	0
Rupture Forcible or traumatic tear or break of an organ or other soft part of the body.	2.11	1	0
Carotid Artery Diseases Pathological conditions involving the CAROTID ARTERIES, including the common, internal, and external carotid arteries. ATHEROSCLEROSIS and TRAUMA are relatively frequent causes of carotid artery pathology.	2.11	1	0
Cancer of Ovary [description not available]	2.49	2	0
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	2.49	2	0
Glial Cell Tumors [description not available]	3.51	1	1
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	3.51	1	1
Cancer of Esophagus [description not available]	2.13	1	0
Cancer of Liver [description not available]	2.53	2	0
Esophageal Neoplasms Tumors or cancer of the ESOPHAGUS.	2.13	1	0
Liver Neoplasms Tumors or cancer of the LIVER.	2.53	2	0
Hepatocellular Carcinoma [description not available]	2.13	1	0
Cancer of Intestines [description not available]	2.13	1	0
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	2.13	1	0
Intestinal Neoplasms Tumors or cancer of the INTESTINES.	2.13	1	0
Carditis [description not available]	2.15	1	0
Myocarditis Inflammatory processes of the muscular walls of the heart (MYOCARDIUM) which result in injury to the cardiac muscle cells (MYOCYTES, CARDIAC). Manifestations range from subclinical to sudden death (DEATH, SUDDEN). Myocarditis in association with cardiac dysfunction is classified as inflammatory CARDIOMYOPATHY usually caused by INFECTION, autoimmune diseases, or responses to toxic substances. Myocarditis is also a common cause of DILATED CARDIOMYOPATHY and other cardiomyopathies.	2.15	1	0
Malignant Melanoma [description not available]	2.71	3	0
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	2.71	3	0
Bone Cancer [description not available]	2.06	1	0
Osteolysis Dissolution of bone that particularly involves the removal or loss of calcium.	2.06	1	0
Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES.	2.06	1	0
Carcinoma, Epidermoid [description not available]	2.98	1	0
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	2.98	1	0
Germinoblastoma [description not available]	2.07	1	0
Lymphoma A general term for various neoplastic diseases of the lymphoid tissue.	2.07	1	0
Alastrim [description not available]	1.93	1	0
Smallpox An acute, highly contagious, often fatal infectious disease caused by an orthopoxvirus characterized by a biphasic febrile course and distinctive progressive skin eruptions. Vaccination has succeeded in eradicating smallpox worldwide. (Dorland, 28th ed)	1.93	1	0

1,4,7-triazacyclononane-n,n',n''-triacetic acid

Description

Cross-References

Synonyms (34)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Protein Targets (1)

Inhibition Measurements

Bioassays (64)

Research

Studies (180)

Market Indicators

Research Demand Index: 10.68

Study Types

1,4,7-triazacyclononane-n,n',n''-triacetic acid

Description

Cross-References

Synonyms (34)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Protein Targets (1)

Inhibition Measurements

Bioassays (64)

Research

Studies (180)

Market Indicators

Research Demand Index: 10.68

Study Types

Related Drugs (90)

Related Conditions (142)